Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi- institutional update

Journal of the American Medical Association

Volumn 277, Issue 18, 1997, Pages 1445-1451

  Partin, Alan W ^a,e   Kattan, Michael W ^c   Subong, Eric N P ^a   Walsh, Patrick C ^a   Wojno, Kirk J ^b   Oesterling, Joseph E ^b   Scardino, Peter T ^c   Pearson, J D ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD LEVEL; CANCER STAGING; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM;

EID: 0030913315     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.18.1445     Document Type: Article

References (23)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer Statistics, 1996. Atlanta, Ga: American Cancer Society; 1996.
2. Morton RA, Steiner MS, Walsh PC. Cancer and control following anatomical radical prostatectomy: an interim report. J Urol. 1991;145:1197-1200.
3. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol Clin North Am. 1993;20:713-725.
4. Pound CR, Partin AW, Epstein JI, Walsh PC. PSA following anatomical radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am. 1997;24:395-406.
5. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-954.
6. Partin AW, Yoo J, Carter HB, et al. The use of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110-114.
7. Baker LH, Hanks G, Gershenson D, et al. National Comprehensive Cancer Network prostate cancer practice guidelines. Oncology. 1996;10(suppl11):265-288.
8. Agresti A. Categorical Data Analysis. New York, NY: John Wiley & Sons Inc; 1990:307-310.
9. Elfron B, Tibshirani R. An Introduction to the Bootstrap. New York, NY: Chapman & Hall; 1993.
10. Oesterling JE, Brendler CB, Epstein JI, Kimball AW Jr, Walsh PC. Correlation of clinical stage, serum prostatic acid phosphatase, and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol. 1987;138:92.
11. Oesterling JE, Chan DW, Epstein JI, et al. Prostate-specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol. 1988; 139:766-772.
12. Ackerman DA, Barry JM, Wicklund RA, Olson N, Lowe BA. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol. 1993;150:1845-1850.
13. Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE. Ability of preoperative serum prostatespecific antigen value to predict pathologic stage and DNA ploidy. Urology. 1993;41:207-216.
14. Roach M III, Marquez C, Hae-Sook Y, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate-specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Physiol. 1994; 28:33-37.
15. Blackwell KL, Bostwick DG, Myers RP, Zincke H, Oesterling JE. Combining prostate-specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostatespecific antigen cancer density. J Urol. 1994;151: 1565-1570.
16. Bluestein DL, Bostwick DG, Bergstralh EJ, Oesterling JE. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol. 1994;151:1315-1320.
17. Sands ME, Zagars GK, Pollack A, von Eschenbach AC. Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancer. Urology. 1994;44: 215-220.
18. Narayan P, Gajendran V, Taylor SP, et al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology. 1995;46:205-212.
19. Narayan P, Fournier G, Gajendran V, et al. Utility of preoperative serum prostate-specific antigen concentation and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology. 1994;44:519-524.
20. Badalament RA, Miller MC, Peller PA, et al. An algorithm for predicting non-organ-confined prostate cancer using the results obtained from sextant core biopsies with prostate-specific antigen level. J Urol. 1996;156:1375-1380.
21. Bostwick DG, Qian J, Bergstralh E, et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol. 1996;155:1361-1367.
22. Rogers E, Gurpinar T, Dillioglugil O, et al. The role of digital rectal examination, biopsy Gleason sum, and prostate-specific antigen in selecting patients who require pelvic lymph node dissections for prostate cancer. Br J Urol. 1996;78:419-425.
23. Kattan MN, Stapleton AMF, Wheeler TM, Scardino PT. Evaluation of a nomogram for predicting pathological stage of men with clinically localized prostate cancer. Cancer. 1996;79:528-537.